Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Free Cash Flow (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Free Cash Flow for 7 consecutive years, with -$8.0 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Free Cash Flow rose 33.31% year-over-year to -$8.0 million, compared with a TTM value of -$22.8 million through Dec 2019, up 55.84%, and an annual FY2024 reading of -$71.3 million, down 111.98% over the prior year.
  • Free Cash Flow was -$8.0 million for Q4 2019 at Larimar Therapeutics, down from -$5.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $3.5 million in Q2 2019 and bottomed at -$18.3 million in Q4 2015.
  • Average Free Cash Flow over 5 years is -$11.5 million, with a median of -$12.0 million recorded in 2017.
  • The sharpest move saw Free Cash Flow tumbled 176.12% in 2015, then skyrocketed 126.07% in 2019.
  • Year by year, Free Cash Flow stood at -$18.3 million in 2015, then surged by 52.68% to -$8.7 million in 2016, then decreased by 13.81% to -$9.9 million in 2017, then fell by 21.04% to -$11.9 million in 2018, then soared by 33.31% to -$8.0 million in 2019.
  • Business Quant data shows Free Cash Flow for LRMR at -$8.0 million in Q4 2019, -$5.8 million in Q3 2019, and $3.5 million in Q2 2019.